Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 3/20 | 0.51 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.51 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.51 |
| ▸ | HTR2A | P28223 | 1/20 | 0.46 |
| ▸ | DPP4 | P27487 | 1/20 | 0.45 |
| ▸ | IDO1 | P14902 | 1/20 | 0.44 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.44 |
| ▸ | MGAM | O43451 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | SI | P14410 | 1/20 | 0.43 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.43 |
| ▸ | MTNR1A | P48039 | 6/20 | 0.41 |
| ▸ | MTNR1B | P49286 | 6/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9470625 | 0.88 | HTR2A (0.48) | SLC6A4SLC6A3SLC6A2HTR2AIDO1 | |
| SCHEMBL9470399 | 0.86 | HTR2A (0.46) | SLC6A4SLC6A3SLC6A2HTR2AIDO1 | |
| SCHEMBL9470524 | 0.81 | IMPDH2 (0.45) | HTR2AGPR84MGAMGAASI | |
| SCHEMBL9470297 | 0.77 | MTNR1B (0.44) | SLC6A4SLC6A3SLC6A2MTNR1AMTNR1B | |
| SCHEMBL25155560 | 0.76 | MGAM (0.48) | HTR2AIDO1GPR84MGAMGAA | |
| SCHEMBL14595569 | 0.74 | MGAM (0.49) | SLC6A4SLC6A3SLC6A2MGAMGAA | |
| SCHEMBL9470319 | 0.74 | LMNA (0.57) | GAAMTNR1AMTNR1BALDH1A1 | |
| SCHEMBL9470861 | 0.73 | ALDH1A1 (0.49) | GPR84MGAMGAASIMGAM2 | |
| SCHEMBL5645456 | 0.73 | IMPDH2 (0.49) | HTR2AGPR84MGAMGAASI | |
| SCHEMBL28944633 | 0.71 | MGAM (0.41) | HTR2AGPR84MGAMGAASI |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8835461-B2 | Substituted 3-hydroxy-4-pyridone derivative | SHIONOGI & CO., LTD. (JP) | 2014-09-16 | — | — | US | disclosed |
| EP-2412708-A1 | SUBSTITUTED 3-HYDROXY-4-PYRIDONE DERIVATIVE | Shionogi&Co., Ltd. (JP) | 2012-02-01 | — | — | EP | disclosed |
| US-20120022255-A1 | SUBSTITUTED 3-HYDROXY-4-PYRIDONE DERIVATIVE | SHIONOGI & CO., LTD. (JP) | 2012-01-26 | — | — | US | disclosed |
| US-7208505-B2 | β3 adrenergic agonists | ELI LILLY AND COMPANY (US) | 2007-04-24 | — | — | US | disclosed |
| US-7208505-B2 | β3 adrenergic agonists | ELI LILLY AND COMPANY (US) | 2007-04-24 | — | — | US | disclosed |
| US-5219859-A | Chloesterol acyltransferase inhibitors; antilipemic agents; antidiabetic agents; atherosclerosis | LIPHA, LYONNAISE INDUSTRIELLE PHARMACEUTIQUE (FR) | 1993-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022255-A1 | SUBSTITUTED 3-HYDROXY-4-PYRIDONE DERIVATIVE | ENDOD1, CNBP, DPP4 | SLC6A4 2033/4885SLC6A3 4094/4885SLC6A2 4362/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.